What is the diagnostic work‑up and initial management for a male patient with hemoglobin 18.7 g/dL and hematocrit 57.4 %?

Diagnostic Work-Up for Elevated Hemoglobin and Hematocrit

This male patient with hemoglobin 18.7 g/dL and hematocrit 57.4% meets the first major criterion for polycythemia vera and requires immediate JAK2 mutation testing, followed by bone marrow biopsy if JAK2 is positive, to establish the diagnosis and prevent thrombotic complications.

Initial Assessment

The hemoglobin of 18.7 g/dL exceeds the WHO diagnostic threshold of 18.5 g/dL for males, and the hematocrit of 57.4% is markedly elevated 1. This fulfills the first major criterion for polycythemia vera (PV) according to the 2016 revised WHO criteria 2.

Critical First Steps

Order JAK2V617F mutation testing immediately - this should be the first molecular test performed in any patient suspected of PV 2. The presence of JAK2V617F or functionally similar mutations (such as JAK2 exon 12) constitutes the second major criterion for PV diagnosis 1.

Diagnostic Algorithm

1. If JAK2V617F is positive:

   • Proceed directly to bone marrow biopsy to confirm hypercellularity with trilineage growth (panmyelosis) 1, 2
   • Measure serum erythropoietin level (typically suppressed in PV) 1
   • Diagnosis of PV requires both major criteria plus one minor criterion 1

2. If JAK2V617F is negative:

   • Test for JAK2 exon 12 mutations 2
   • If still negative, bone marrow biopsy becomes essential to differentiate from secondary causes
   • Search for complementary clonal markers (ASXL1, EZH2, IDH1/IDH2, SRSF2) if suspicion remains high 2

Secondary Causes to Exclude

Before finalizing a PV diagnosis, systematically exclude:

• Hypoxia-related causes: Obtain pulse oximetry and arterial blood gas. Check for chronic lung disease, sleep apnea, smoking history (carbon monoxide exposure), or high-altitude residence 3, 4
• Renal pathology: Measure serum erythropoietin level and consider renal imaging if elevated (renal cell carcinoma, renal artery stenosis)
• Relative erythrocytosis: Assess for dehydration, obesity, diuretic use, or stress-induced hemoconcentration 3
• Testosterone or anabolic steroid use

Important Caveats

Iron deficiency can mask PV - if ferritin is low or iron studies suggest deficiency, the guidelines acknowledge that hemoglobin may be artificially lowered 1. In routine clinical practice, you should not be prevented from making a working diagnosis of PV in the presence of iron deficiency, even if WHO criteria aren't fully met after iron replacement 1.

Altitude adjustment matters - normal hemoglobin and hematocrit values increase significantly with altitude. At 4000 meters, normal male hematocrit can reach 61% 4. However, this patient's values would still be elevated even accounting for moderate altitude 5.

Risk Stratification and Initial Management

Once PV is diagnosed, immediately stratify thrombotic risk:

• High-risk: Age ≥60 years OR prior thrombosis history 2
• Low-risk: Age <60 years AND no thrombosis history 2

Initiate aspirin therapy (typically 81-100 mg daily) for all patients unless contraindicated, as thrombosis is the primary cause of morbidity and mortality in PV 2.

For high-risk patients: Begin cytoreductive therapy (hydroxyurea is first-line) in addition to aspirin and phlebotomy 2.

For low-risk patients: Phlebotomy to maintain hematocrit <45% plus aspirin is the standard approach 1, 2.

Critical Pitfall

Do not delay workup - this patient is at immediate risk for thrombotic events including stroke, myocardial infarction, and unusual site thromboses (portal vein, mesenteric, cerebral) 6. Even patients with "masked PV" presenting with normal blood counts can develop life-threatening thrombosis 6. The presence of leukocytosis further increases thrombotic risk 2.